Skip to main content
See details

Reimbursement summary for angioplasty of arteries of lower extremities

This post presents an extract from our reimbursement analysis for angioplasty of arteries lower extremities using plain and drug-coated balloons (DCBs) for peripheral artery disease in England, France and Germany. Plain balloon angioplasty is reimbursement via DRG solely and DCBs are reimbursement via combination of DRG and add-on reimbursement.
See details

Acceptance of applications for conditional reimbursement is opened in the Netherlands

Conditional reimbursement for the period of up to 4 years can be available for promising technologies, which did not meet criteria for “state of science and practice” in the assessments of the Care Institute Netherlands (Zorginstituut Nederland).

The pre-condition for submission is available assessment from the Zorginstituut Nederland, which did not find evidence sufficient to recommend technology for reimbursement within basic insurance package, but mentioned possibility of conditional reimbursement.

During period of reimbursement, clinical trial shall be conducted in the Netherlands to bridge evidence in relation to effectiveness and cost-effectiveness. The maximum duration of conditional reimbursement is 4 years (in exceptional cases a longer duration of up to 7 years is possible).

The period for submitting dossiers for care forms that may be eligible for conditional admission to the basic package by 2020 has started from 15th February. Requests can be submitted till 15th of May 2018.

See details of news in Dutch here.

Subscribe to our newsletter delivered every second week not to miss important reimbursement information.